Logo

American Heart Association

  12
  0


Final ID: MDP1111

Large-Scale Proteomics Identifies Novel Circulating Markers of Pulmonary Hypertension: the Atherosclerosis Risk in Communities Study

Abstract Body (Do not enter title and authors here): Introduction: Biomarkers for early-stage pulmonary hypertension (PH) are unavailable in clinical practice.

Aims: We aimed to discover novel plasma biomarkers associated with pulmonary pressure and PH.

Methods: Among participants in the community-based Atherosclerosis Risk in Communities (ARIC) cohort study who underwent protocol echocardiography at the 5th study visit (2011-2013), had assessable pulmonary artery systolic pressure (PASP), and were free of diagnosed heart failure (HF) or pulmonary disease, we measured 4,955 plasma proteins (SomaScan aptamer-affinity assay). Participants also performed spirometry at the same study visit. We assessed cross sectional associations of individual proteins with PASP using multivariable linear regression adjusted for demographic and clinical covariates. We further assessed the associations of candidate proteins with cardiac and pulmonary function to explore mechanisms of association with PASP. Additionally, we performed two-sample Mendelian Randomization (MR) analyses using cis-pQTLs to identify potential causal associations.

Results: Among 2,015 participants included, mean age was 75±5 years, 64% were female, 17% reported Black race, and LVEF was 66±6%. Mean PASP was 28±6 mmHg. Twenty-five protein aptamers (21 unique proteins) were associated with PASP at Bonferroni significance (Figure A). Of these 21 candidate proteins, the 16 associated with higher PASP were also generally associated with greater LV mass, lower LVEF, and worse LV diastolic function (specially higher LA volume index and lower LA reservoir strain) and worse spirometric measures (Figure B). The 5 proteins associated with lower PASP were generally associated with better LV structure and function. Of these 21 proteins, two-sample MR identified one protein with potential causal effects on pulmonary arterial hypertension (PROC), one with effects on LV size (ENG), and 4 with effects on pulmonary function (ANGPT2, CLSTN2, ICAM5, SPON1).

Conclusion: We identified novel protein markers of pulmonary pressure, with potential causal associations related to the pathological substrate for types 1, 2 and 3 PH.
  • Giugni, Fernando  ( UT Southwestern Medical Center , Yorktown , Virginia , United States )
  • Santos, Mario  ( CHUP , Porto , Portugal )
  • Yang, Yimin  ( UT Southwestern Medical Center , Yorktown , Virginia , United States )
  • Lamberson, Victoria  ( UT Southwestern Medical Center , Yorktown , Virginia , United States )
  • Claggett, Brian  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • Hoogeveen, Ron  ( BAYLOR COLLEGE MEDICINE , Houston , Texas , United States )
  • Ballantyne, Christie  ( BAYLOR COLLEGE MEDICINE , Houston , Texas , United States )
  • Yu, Bing  ( UNIV OF TX HEALTH SCI CTR HOUSTON , Houston , Texas , United States )
  • Shah, Amil  ( UT Southwestern Medical Center , Yorktown , Virginia , United States )
  • Author Disclosures:
    Fernando Giugni: DO NOT have relevant financial relationships | Mario Santos: No Answer | Yimin Yang: DO NOT have relevant financial relationships | Victoria Lamberson: DO NOT have relevant financial relationships | Brian Claggett: DO have relevant financial relationships ; Consultant:Cardior:Active (exists now) ; Consultant:Eli Lilly:Active (exists now) ; Consultant:CVRx:Past (completed) ; Consultant:Intellia:Active (exists now) ; Consultant:Cytokinetics:Past (completed) ; Consultant:Cardurion:Active (exists now) | Ron Hoogeveen: DO have relevant financial relationships ; Consultant:Denka Seiken:Active (exists now) | Christie Ballantyne: DO have relevant financial relationships ; Independent Contractor:Abbott Diagnostic, Akcea, Amgen, Arrowhead, Ionis, Lilly, Merck, New Amsterdam, Novartis, Novo Nordisk:Active (exists now) ; Consultant:Abbott Diagnostic, Amgen, Arrowhead, Astra Zeneca, Denka Seiken, Eli Lilly, Esperion, Illumina, Ionis, Merck, New Amsterdam, Novartis, Novo Nordisk, Roche Diagnostic, TenSixteen Bio:Active (exists now) | Bing Yu: DO NOT have relevant financial relationships | Amil Shah: DO have relevant financial relationships ; Advisor:Philips Ultrasound:Past (completed) ; Advisor:Janssen:Past (completed)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Metabolic and Proteomic Regulators of Pulmonary Hypertension: From Molecules to Man

Sunday, 11/17/2024 , 11:10AM - 12:35PM

Moderated Digital Poster Session

More abstracts on this topic:
Alpha-1-acid glycoprotein is a potential serum Biomarker for Cerebral Amyloid Angiopathy

Nishigaki Akisato, Matsuura Keita, Ii Yuichiro, Oikawa Shinji, Tomimoto Hidekazu, Shindo Akihiro, Ishikawa Hidehiro, Nishiguchi Yamato, Tachibana Kei, Kato Natsuko, Matsuda Kana, Mori Yurie, Utsunomiya Takaya, Matsuyama Hirofumi

Associations of Pulmonary Hypertension and Lung Cancer: A Prospective Cohort Study of Half a Million UK Biobank Participants

Zhu Fang, Zhang Qian, Luo Qingquan

More abstracts from these authors:
Large Scale Proteomics Identifies Circulating Biomarkers Relating Atrial Fibrillation to Heart Failure: the Atherosclerosis Risk in Communities Study

Giugni Fernando, Shah Amil, Lamberson Victoria, Yang Yimin, Chen Lin, Matsushita Kunihiro, Hoogeveen Ron, Ballantyne Christie, Coresh Josef, Yu Bing

Sex-Specific Associations of Plasma Proteins with HF Risk: The Atherosclerosis in Communities (ARIC) Study

Lamberson Victoria, Yang Yimin, Claggett Brian, Hoogeveen Ron, Ballantyne Christie, Coresh Joe, Yu Bing, Shah Amil

You have to be authorized to contact abstract author. Please, Login
Not Available